We have recently shown that BCG (Bacillus Calmette-Guérin) vaccination in healthy volunteers induces epigenetic reprogramming of monocytes, leading to increased cytokine production in response to nonrelated pathogens for up to 3 months after vaccination. This phenomenon was named ‘trained immunity'. In the present study we assessed whether BCG was able to induce long-lasting effects on both trained immunity and heterologous T helper 1 (Th1) and Th17 immune responses 1 year after vaccination. The production of TNFα and IL-1β to mycobacteria or unrelated pathogens was higher after 2 weeks and 3 months postvaccination, but these effects were less pronounced 1 year after vaccination. However, monocytes recovered 1 year after vaccination had an increased expression of pattern recognition receptors such as CD14, Toll-like receptor 4 (TLR4) and mannose receptor, and this correlated with an increase in proinflammatory cytokine production after stimulation with the TLR4 ligand lipopolysaccharide. The heterologous production of Th1 (IFN-γ) and Th17 (IL-17 and IL-22) immune responses to nonmycobacterial stimulation remained strongly elevated even 1 year after BCG vaccination. In conclusion, BCG induces sustained changes in the immune system associated with a nonspecific response to infections both at the level of innate trained immunity and at the level of heterologous Th1/Th17 responses.

Keywords:
Innate immunity, BCG vaccination, Trained immunity
1.
Levine MI, Sackett MF: Results of BCG immunization in New York City. Am Rev Tuberc 1946;53:517-532.
2.
Aronson JD: Protective vaccination against tuberculosis, with special reference to BCG vaccine. Minn Med 1948;31:1336.
3.
Ferguson RG, Simes AB: BCG vaccination of Indian infants in Saskatchewan. Tubercle 1949;30:5-11.
4.
Rosenthal SR, Loewinsohn E, Graham ML, Liveright D, Thorne MG, Johnson V: BCG vaccination in tuberculous households. Am Rev Respir Dis 1961;84:690-704.
5.
Naeslund C: Expérience de vaccination par le BCG dans la province du Norrbotten (Suède). Rev Tuberc 1931;12:617-636.
6.
Velema JP, Alihonou EM, Gandaho T, Hounye FH: Childhood mortality among users and non-users of primary health care in a rural West African community. Int J Epidemiol 1991;20:474-479.
7.
Niobey FM, Duchiade MP, Vasconcelos AG, de Carvalho ML, Leal MC, Valente JG: Risk factors for death caused by pneumonia in children younger than 1 year old in a metropolitan region of southeastern Brazil: a case-control study (in Portuguese). Rev Saude Publica 1992;26:229-238.
8.
Kristensen I, Aaby P, Jensen H: Routine vaccinations and child survival: follow-up study in Guinea-Bissau, West Africa. BMJ 2000;321:1435-1438.
9.
Garly ML, Martins CL, Bale C, Balde MA, Hedegaard KL, Gustafson P, Lisse IM, Whittle HC, Aaby P: BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa: a non-specific beneficial effect of BCG? Vaccine 2003;21:2782-2790.
10.
Vaugelade J, Pinchinat S, Guiella G, Elguero E, Simondon F: Non-specific effects of vaccination on child survival: prospective cohort study in Burkina Faso. BMJ 2004;329:1309.
11.
Roth A, Garly ML, Jensen H, Nielsen J, Aaby P: Bacillus calmette-guerin vaccination and infant mortality. Expert Rev Vaccines 2006;5:277-293.
12.
Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, Newport M, Marchant A, Aaby P: Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine 2005;23:1251-1257.
13.
Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, Stensballe L, Diness BR, Lausch KR, Lund N, Biering-Sorensen S, Whittle H, Benn CS: Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011;204:245-252.
14.
Biering-Sorensen S, Aaby P, Napirna BM, Roth A, Ravn H, Rodrigues A, Whittle H, Benn CS: Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J 2012;31:306-308.
15.
Welsh RM, Selin LK: No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002;2:417-426.
16.
Netea MG, Quintin J, van der Meer JW: Trained immunity: a memory for innate host defense. Cell Host Microbe 2011;9:355-361.
17.
Durrant WE, Dong X: Systemic acquired resistance. Ann Rev Phytopathol 2004;42:185-209.
18.
Pham LN, Dionne MS, Shirasu-Hiza M, Schneider DS: A specific primed immune response in Drosophila is dependent on phagocytes. PLoS Pathog 2007;3:e26.
19.
Rodrigues J, Brayner FA, Alves LC, Dixit R, Barillas-Mury C: Hemocyte differentiation mediates innate immune memory in Anopheles gambiae mosquitoes. Science 2010;329:1353-1355.
20.
Sun JC, Beilke JN, Lanier LL: Adaptive immune features of natural killer cells. Nature 2009;457:557-561.
21.
Quintin J, Saeed S, Martens JH, Giamarellos-Bourboulis EJ, Ifrim DC, Logie C, Jacobs L, Jansen T, Kullberg BJ, Wijmenga C, Joosten LA, Xavier RJ, van der Meer JW, Stunnenberg HG, Netea MG: Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 2012;12:223-232.
22.
Gorhe DS: Inhibition of multiplication of foot and mouth disease virus in adult mice pretreated with Freund's complete adjuvant. Nature 1967;216:1242-1244.
23.
Chedid L, Parant M, Parant F, Lefrancher P, Choay J, Lederer E: Enhancement of nonspecific immunity to klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci USA 1977;74:2089-2093.
24.
van ‘t Wout JW, Poell R, van FR: The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol 1992;36:713-719.
25.
Sakuma T, Suenaga T, Yoshida I, Azuma M: Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection. Infect Immun 1983;42:567-573.
26.
Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ, van der Meer JW, van Crevel R, Netea MG: Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012;109:17537-17542.
27.
Mackaness GB: The immunological basis of acquired cellular resistance. J Exp Med 1964;120:105-120.
28.
Selin LK, Varga SM, Wong IC, Welsh RM: Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 1998;188:1705-1715.
29.
Mackaness GB: The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med 1969;129:973-992.
30.
Berg RE, Crossley E, Murray S, Forman J: Memory CD8+ T cells provide innate immune protection against listeria monocytogenes in the absence of cognate antigen. J Exp Med 2003;198:1583-1593.
31.
van de Veerdonk FL, Marijnissen RJ, Kullberg BJ, Koenen HJ, Cheng SC, Joosten I, van den Berg WB, Williams DL, van der Meer JW, Joosten LA, Netea MG: The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 2009;5:329-340.
32.
Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, Zou W: Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 2007;179:1423-1426.
33.
Faustman DL, Wang L, Okubo Y, Burger D, Ban L, Man G, Zheng H, Schoenfeld D, Pompei R, Avruch J, Nathan DM: Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One 2012;7:e41756.
34.
Rousseau MC, Parent ME, St-Pierre Y: Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. Pediatr Allergy Immunol 2008;19:438-448.
35.
Akashi-Takamura S, Miyake K: TLR accessory molecules. Curr Opin Immunol 2008;20:420-425.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.